US 12,440,541 B2
Methods for expanding and activating γσ T cells for the treatment of cancer and related malignancies
Monique Dao, Houston, TX (US); Steffen Walter, Houston, TX (US); Melinda Mata, Missouri City, TX (US); Aleksandra Norwicka, Nowicka, TX (US); Yannick Bulliard, Houston, TX (US); Sarah Missell, Tuebingen (DE); Sabrina Kuttruff-Coqui, Filderstadt-Sielmingen (DE); and Norbert Hilf, Kirchentellinsfurt (DE)
Assigned to Immatics US, Inc., Stafford, TX (US)
Filed by IMMATICS US, INC., Houston, TX (US)
Filed on May 18, 2023, as Appl. No. 18/319,677.
Application 18/319,677 is a continuation of application No. 16/200,308, filed on Nov. 26, 2018, granted, now 11,690,872.
Claims priority of provisional application 62/591,041, filed on Nov. 27, 2017.
Claims priority of application No. 102017127984.9 (DE), filed on Nov. 27, 2017.
Prior Publication US 2024/0115609 A1, Apr. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 31/663 (2006.01); A61K 31/675 (2006.01); A61K 38/20 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); C07K 14/54 (2006.01); C07K 14/55 (2006.01); C12N 5/00 (2006.01); C12N 5/0783 (2010.01); C12N 15/62 (2006.01); C12N 15/85 (2006.01); A61K 35/12 (2015.01); A61K 40/50 (2025.01); C07K 16/28 (2006.01)
CPC A61K 38/2013 (2013.01) [A61K 31/663 (2013.01); A61K 31/675 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/32 (2025.01); A61K 40/428 (2025.01); C07K 14/5443 (2013.01); C07K 14/55 (2013.01); C12N 5/0018 (2013.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); C12N 15/62 (2013.01); C12N 15/8509 (2013.01); A61K 2035/122 (2013.01); A61K 2035/124 (2013.01); A61K 40/50 (2025.01); C07K 16/2809 (2013.01); C12N 2501/155 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/515 (2013.01); C12N 2501/998 (2013.01); C12N 2740/10043 (2013.01)] 19 Claims
 
1. A method of preparing and administering engineered γδ T cells for cancer immunotherapy comprising:
obtaining γδ T cells,
activating the obtained γδ T cells in the presence of an aminobisphosphonate, interleukin 2 (IL-2), and interleukin 15 (IL-15),
transducing the activated γδ T cells,
expanding the transduced γδ T cells in the absence of an aminobisphosphonate and in the presence of IL-2 and IL-15 to produce the engineered γδ T cells,
wherein the fold-expansion of the engineered γδ T cells is about 10,000-fold to about 35,000-fold, and
administering at least 105 of the engineered γδ T-cells to a patient who has cancer.